Production of interleukin-6 by skeletal myotubes: Role of reactive oxygen species

Ioanna Kosmidou, Theodoros Vassilakopoulos, Angeliki Xagorari, Spyros Zakynthinos, Andreas Papapetropoulos, Charis Roussos

Research output: Contribution to journalArticle

138 Citations (Scopus)

Abstract

In the present study we have tested the ability of reactive oxygen species (ROS) to stimulate the production of interleukin (IL)-6 from skeletal myocytes. Differentiated C2C12 murine skeletal muscle cells (myotubes) exposed to pyrogallol (PYR), xanthine/xanthine-oxidase (X/XO), or H2O2 for 24 h exhibited a concentration-dependent increase in IL-6 production. Unlike myotubes, incubation of myoblasts and endothelial cells with X/XO or PYR did not result in increased IL-6 release. In myotubes, superoxide dismutase and catalase blocked the ROS-induced IL-6 release. Exposure of myotubes to H2O2 increased steady-state IL-6 mRNA levels, and pretreatment of myotubes with actinomycin D or cycloheximide abolished the ROS-induced IL-6 production. In addition, pretreatment of cells with N-acetyl-cysteine blocked tumor necrosis factor (TNF)-α-induced IL-6 release, suggesting that endogenously produced ROS participate in IL-6 production. Myotubes stimulated with H2O2 exhibited increased IκB-α phosphorylation and degradation, and treatment of C2C12 with ROS-generating agents increased activator protein (AP)-1 and nuclear factor (NF)-κB-dependent promoter activity. Finally, preincubation of myotubes with the pharmacologic inhibitor of NF-κB, diethyldithiocarbamate, or transient transfection with an IκB-α mutant, inhibited the ROS-stimulated IL-6 release. In conclusion, ROS stimulate IL-6 production from skeletal myotubes in a manner that involves transcriptional activation of the IL-6 gene through an NF-κB-dependent pathway.

Original languageEnglish (US)
Pages (from-to)587-593
Number of pages7
JournalAmerican journal of respiratory cell and molecular biology
Volume26
Issue number5
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

Skeletal Muscle Fibers
Interleukin-6
Reactive Oxygen Species
Pyrogallol
Xanthine
Xanthine Oxidase
Acetylcysteine
Cells
Ditiocarb
Phosphorylation
Myoblasts
Endothelial cells
Transcription Factor AP-1
Dactinomycin
Cycloheximide
Catalase
Muscle Cells
Transcriptional Activation
Superoxide Dismutase
Transfection

ASJC Scopus subject areas

  • Molecular Biology
  • Pulmonary and Respiratory Medicine
  • Clinical Biochemistry
  • Cell Biology

Cite this

Production of interleukin-6 by skeletal myotubes : Role of reactive oxygen species. / Kosmidou, Ioanna; Vassilakopoulos, Theodoros; Xagorari, Angeliki; Zakynthinos, Spyros; Papapetropoulos, Andreas; Roussos, Charis.

In: American journal of respiratory cell and molecular biology, Vol. 26, No. 5, 01.01.2002, p. 587-593.

Research output: Contribution to journalArticle

Kosmidou, Ioanna ; Vassilakopoulos, Theodoros ; Xagorari, Angeliki ; Zakynthinos, Spyros ; Papapetropoulos, Andreas ; Roussos, Charis. / Production of interleukin-6 by skeletal myotubes : Role of reactive oxygen species. In: American journal of respiratory cell and molecular biology. 2002 ; Vol. 26, No. 5. pp. 587-593.
@article{ef80d456aafd4920ba5b0b58b4e3872f,
title = "Production of interleukin-6 by skeletal myotubes: Role of reactive oxygen species",
abstract = "In the present study we have tested the ability of reactive oxygen species (ROS) to stimulate the production of interleukin (IL)-6 from skeletal myocytes. Differentiated C2C12 murine skeletal muscle cells (myotubes) exposed to pyrogallol (PYR), xanthine/xanthine-oxidase (X/XO), or H2O2 for 24 h exhibited a concentration-dependent increase in IL-6 production. Unlike myotubes, incubation of myoblasts and endothelial cells with X/XO or PYR did not result in increased IL-6 release. In myotubes, superoxide dismutase and catalase blocked the ROS-induced IL-6 release. Exposure of myotubes to H2O2 increased steady-state IL-6 mRNA levels, and pretreatment of myotubes with actinomycin D or cycloheximide abolished the ROS-induced IL-6 production. In addition, pretreatment of cells with N-acetyl-cysteine blocked tumor necrosis factor (TNF)-α-induced IL-6 release, suggesting that endogenously produced ROS participate in IL-6 production. Myotubes stimulated with H2O2 exhibited increased IκB-α phosphorylation and degradation, and treatment of C2C12 with ROS-generating agents increased activator protein (AP)-1 and nuclear factor (NF)-κB-dependent promoter activity. Finally, preincubation of myotubes with the pharmacologic inhibitor of NF-κB, diethyldithiocarbamate, or transient transfection with an IκB-α mutant, inhibited the ROS-stimulated IL-6 release. In conclusion, ROS stimulate IL-6 production from skeletal myotubes in a manner that involves transcriptional activation of the IL-6 gene through an NF-κB-dependent pathway.",
author = "Ioanna Kosmidou and Theodoros Vassilakopoulos and Angeliki Xagorari and Spyros Zakynthinos and Andreas Papapetropoulos and Charis Roussos",
year = "2002",
month = "1",
day = "1",
doi = "10.1165/ajrcmb.26.5.4598",
language = "English (US)",
volume = "26",
pages = "587--593",
journal = "American Journal of Respiratory Cell and Molecular Biology",
issn = "1044-1549",
publisher = "American Thoracic Society",
number = "5",

}

TY - JOUR

T1 - Production of interleukin-6 by skeletal myotubes

T2 - Role of reactive oxygen species

AU - Kosmidou, Ioanna

AU - Vassilakopoulos, Theodoros

AU - Xagorari, Angeliki

AU - Zakynthinos, Spyros

AU - Papapetropoulos, Andreas

AU - Roussos, Charis

PY - 2002/1/1

Y1 - 2002/1/1

N2 - In the present study we have tested the ability of reactive oxygen species (ROS) to stimulate the production of interleukin (IL)-6 from skeletal myocytes. Differentiated C2C12 murine skeletal muscle cells (myotubes) exposed to pyrogallol (PYR), xanthine/xanthine-oxidase (X/XO), or H2O2 for 24 h exhibited a concentration-dependent increase in IL-6 production. Unlike myotubes, incubation of myoblasts and endothelial cells with X/XO or PYR did not result in increased IL-6 release. In myotubes, superoxide dismutase and catalase blocked the ROS-induced IL-6 release. Exposure of myotubes to H2O2 increased steady-state IL-6 mRNA levels, and pretreatment of myotubes with actinomycin D or cycloheximide abolished the ROS-induced IL-6 production. In addition, pretreatment of cells with N-acetyl-cysteine blocked tumor necrosis factor (TNF)-α-induced IL-6 release, suggesting that endogenously produced ROS participate in IL-6 production. Myotubes stimulated with H2O2 exhibited increased IκB-α phosphorylation and degradation, and treatment of C2C12 with ROS-generating agents increased activator protein (AP)-1 and nuclear factor (NF)-κB-dependent promoter activity. Finally, preincubation of myotubes with the pharmacologic inhibitor of NF-κB, diethyldithiocarbamate, or transient transfection with an IκB-α mutant, inhibited the ROS-stimulated IL-6 release. In conclusion, ROS stimulate IL-6 production from skeletal myotubes in a manner that involves transcriptional activation of the IL-6 gene through an NF-κB-dependent pathway.

AB - In the present study we have tested the ability of reactive oxygen species (ROS) to stimulate the production of interleukin (IL)-6 from skeletal myocytes. Differentiated C2C12 murine skeletal muscle cells (myotubes) exposed to pyrogallol (PYR), xanthine/xanthine-oxidase (X/XO), or H2O2 for 24 h exhibited a concentration-dependent increase in IL-6 production. Unlike myotubes, incubation of myoblasts and endothelial cells with X/XO or PYR did not result in increased IL-6 release. In myotubes, superoxide dismutase and catalase blocked the ROS-induced IL-6 release. Exposure of myotubes to H2O2 increased steady-state IL-6 mRNA levels, and pretreatment of myotubes with actinomycin D or cycloheximide abolished the ROS-induced IL-6 production. In addition, pretreatment of cells with N-acetyl-cysteine blocked tumor necrosis factor (TNF)-α-induced IL-6 release, suggesting that endogenously produced ROS participate in IL-6 production. Myotubes stimulated with H2O2 exhibited increased IκB-α phosphorylation and degradation, and treatment of C2C12 with ROS-generating agents increased activator protein (AP)-1 and nuclear factor (NF)-κB-dependent promoter activity. Finally, preincubation of myotubes with the pharmacologic inhibitor of NF-κB, diethyldithiocarbamate, or transient transfection with an IκB-α mutant, inhibited the ROS-stimulated IL-6 release. In conclusion, ROS stimulate IL-6 production from skeletal myotubes in a manner that involves transcriptional activation of the IL-6 gene through an NF-κB-dependent pathway.

UR - http://www.scopus.com/inward/record.url?scp=0036010523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036010523&partnerID=8YFLogxK

U2 - 10.1165/ajrcmb.26.5.4598

DO - 10.1165/ajrcmb.26.5.4598

M3 - Article

C2 - 11970911

AN - SCOPUS:0036010523

VL - 26

SP - 587

EP - 593

JO - American Journal of Respiratory Cell and Molecular Biology

JF - American Journal of Respiratory Cell and Molecular Biology

SN - 1044-1549

IS - 5

ER -